Andrew Dudum Sells 188,888 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $12.54, for a total value of $2,368,655.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Andrew Dudum also recently made the following trade(s):

• On Thursday, April 4th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.97, for a total transaction of $2,827,653.36.
• On Wednesday, March 20th, Andrew Dudum sold 50,361 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.34, for a total transaction of $822,898.74.
• On Tuesday, February 13th, Andrew Dudum sold 97,208 shares of Hims & Hers Health stock. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64.

Hims & Hers Health Price Performance

NYSE HIMS opened at $11.26 on Monday. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $17.16. The firm has a market capitalization of $2.41 billion, a P/E ratio of -102.36 and a beta of 0.97. The business’s 50-day simple moving average is $14.01 and its 200-day simple moving average is $10.31.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The company had revenue of $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. During the same period in the previous year, the firm earned ($0.05) earnings per share. Hims & Hers Health’s revenue for the quarter was up 47.4% on a year-over-year basis. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.11 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the stock. Graham Capital Management L.P. raised its holdings in shares of Hims & Hers Health by 39.4% during the 3rd quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock valued at $2,141,000 after buying an additional 96,277 shares during the period. Swiss National Bank grew its position in Hims & Hers Health by 9.2% in the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock valued at $1,945,000 after acquiring an additional 26,100 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Hims & Hers Health by 3.1% during the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after purchasing an additional 428,671 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Hims & Hers Health by 11.5% in the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock valued at $3,551,000 after purchasing an additional 58,288 shares during the period. Finally, Must Asset Management Inc. acquired a new stake in Hims & Hers Health during the 3rd quarter valued at $1,596,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of recent research reports. SVB Leerink assumed coverage on Hims & Hers Health in a research note on Monday, February 26th. They issued a “market perform” rating and a $10.00 target price on the stock. Citigroup increased their price objective on Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Imperial Capital raised shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 target price for the company in a research note on Wednesday, February 28th. Canaccord Genuity Group initiated coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Piper Sandler boosted their price objective on shares of Hims & Hers Health from $9.00 to $11.00 and gave the company a “neutral” rating in a research report on Tuesday, February 27th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.85.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.